Anacor Pharmaceuticals Inc. (ANAC) Drops 10.01% on January 11

Equities Staff |

Anacor Pharmaceuticals Inc. (ANAC) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 10.01% to $86.21, a loss of $-9.59 per share. Starting at an opening price of $96.87 a share, the stock traded between $86.18 and $101.61 over the course of the trading day. Volume was 853,460 shares over 9,964 trades, against an average daily volume of 755,207 shares and a total float of 44.12 million.

The losses send Anacor Pharmaceuticals Inc. down to a market cap of $3.8 billion. In the last year, Anacor Pharmaceuticals Inc. has traded between $156.93 and $32.04, and its 50-day SMA is currently $110.42 and 200-day SMA is $101.48.

Anacor Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Anacor Pharmaceuticals Inc. is based out of Palo Alto, CA and has some 100 employees. Its CEO is Paul L. Berns.

For a complete fundamental analysis analysis of Anacor Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for ANAC. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Breathtec BioMedical Inc.

Breathtec Biomedical Inc is a medical diagnostics company. It is engaged in developing & commercializing breath analysis devices for the early detection of infections & life threatening diseases including cancers,…

Private Markets


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.